Clinical efficacy of cardiovascular surgery combined with preoperative immunosuppression for Behçet's disease: A retrospective cohort study in a single center
- VernacularTitle:心血管外科手术联合术前免疫抑制治疗白塞病有效性的单中心回顾性队列研究
- Author:
Fanyu CHEN
1
;
Lanxin YE
2
;
Ziyan XU
3
;
Oudi CHEN
4
;
Lixi GAN
2
;
Hongkun QING
1
;
Weiteng WANG
2
;
Xin LI
1
;
Yang CUI
5
;
Xuhua JIAN
1
Author Information
1. Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510010, P. R. China
2. Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510010, P. R. China
3. The Second Medical College of Southern Medical University, Guangzhou, 510280, P. R. China
4. Department of Echocardiography, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510010, P. R. China
5. Department of Rheumatology and Immunology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510010, P. R. China
- Publication Type:Journal Article
- Keywords:
Behçet’s disease;
cardiovascular surgery;
immunosuppression;
complications;
survival rate
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2026;33(09):1448-1456
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effectiveness of preoperative immunosuppressive therapy combined with surgical intervention for Behçet's disease. Methods A retrospective study was conducted on Behçet's disease patients who underwent cardiovascular surgery at Guangdong Provincial People's Hospital from 2012 to 2021. Patients were divided into an immunosuppressive group and a non-immunosuppressive group based on whether they received immunosuppressive therapy before surgery. The complications and long-term survival rates of the two groups were analyzed. Results A total of 28 patients were included, among which 2 patients underwent reoperation, a total of 30 surgeries were performed, including 16 males (53.3%), and the age at diagnosis was 37 (31, 45) years. There were 15 surgeries in the immunosuppressive group and 15 surgeries in the non-immunosuppressive group. Compared with the non-immunosuppressive group, the incidence of complications during hospitalization in the immunosuppressive group was lower (13.3% vs. 53.3%, P=0.008). One patient died in hospital, and the rest were discharged and followed up, with a median follow-up time of 38.7 (15.1, 57.3) months, and there was no statistically significant difference in long-term survival rate between the two groups (73.3% vs. 93.3%, P=0.158). There was no statistical difference in the cumulative incidence of complications one month (20% vs. 53%, P=0.058) and one year (27% vs. 60%, P=0.065) after surgery between the immunosuppressive group and the non-immunosuppressive group, but there was a statistical difference in the cumulative incidence of complications three years after surgery (47% vs. 92%, P=0.002). Conclusion Surgical treatment can save lives in Behçet's disease patients with cardiovascular diseases, but the incidence of postoperative complications is high. Timely use of immunosuppressants before cardiovascular surgery can reduce the incidence of postoperative complications.
